Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Mass. Movers

Alnylam releases trial results

Continue reading below

Alnylam Pharmaceuticals Inc. released top-line results from its phase 2b trial for its treatment of respiratory syncytial virus, an infection in lung transplant patients. The Cambridge company said the trial was a randomized, double-blind, placebo-controlled study of the drug, ALN-RSV01, in infected lung transplant patients. “We believe that these data provide important evidence’’ of a reduction in the incidence of new disease in patients, said one Alnylam executive.

Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week